Chronic myeloid leukemia treatment with recombinant α2-interferon

I. Strozha; V. Petukhov; D. Bondare; G. Feldmane; A. Duks; I. Teilane; I. Medne; M. Mauritsas; L. Grinberga

Chronic myeloid leukemia treatment with recombinant α₂-interferon

I. Strozha, V. Petukhov, D. Bondare, G. Feldmane, A. Duks, I. Teilane, I. Medne, M. Mauritsas, L. Grinberga

Research output: Contribution to journal › Article › peer-review

Abstract

A trial has been conducted of recombinant α₂-interferon (reaferon) used in 32 patients with Ph'-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.

Original language	English
Pages (from-to)	62-66
Number of pages	5
Journal	Terapevticheskii Arkhiv
Volume	65
Issue number	10
Publication status	Published - 1993
Externally published	Yes

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{73f97cc5e422402d8b0b1d7c241525f0,

title = "Chronic myeloid leukemia treatment with recombinant α2-interferon",

abstract = "A trial has been conducted of recombinant α2-interferon (reaferon) used in 32 patients with Ph'-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.",

author = "I. Strozha and V. Petukhov and D. Bondare and G. Feldmane and A. Duks and I. Teilane and I. Medne and M. Mauritsas and L. Grinberga",

year = "1993",

language = "English",

volume = "65",

pages = "62--66",

journal = "Terapevticheskii Arkhiv",

issn = "0040-3660",

publisher = "Consilium MediCum",

number = "10",

}

TY - JOUR

T1 - Chronic myeloid leukemia treatment with recombinant α2-interferon

AU - Strozha, I.

AU - Petukhov, V.

AU - Bondare, D.

AU - Feldmane, G.

AU - Duks, A.

AU - Teilane, I.

AU - Medne, I.

AU - Mauritsas, M.

AU - Grinberga, L.

PY - 1993

Y1 - 1993

N2 - A trial has been conducted of recombinant α2-interferon (reaferon) used in 32 patients with Ph'-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.

AB - A trial has been conducted of recombinant α2-interferon (reaferon) used in 32 patients with Ph'-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0027758134&partnerID=8YFLogxK

M3 - Article

C2 - 8296238

AN - SCOPUS:0027758134

SN - 0040-3660

VL - 65

SP - 62

EP - 66

JO - Terapevticheskii Arkhiv

JF - Terapevticheskii Arkhiv

IS - 10

ER -